Pharmaceuticals
CStone announces China's NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
* This supplementary new drug application was filed for the fourth indication for sugemalimab inChina, following applications for stage III and stage IV non-small cell lung cancer and relapsed or refractory extranodal NK/T cell lymphoma. If approved, sugemalimab would be the first PD-L1 monoclo...
2023-02-28 08:05
3874
Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration
ROCKVILLE, Md. and SUZHOU, China, Feb. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-02-28 08:00
3346
Everest Medicines Hosts Ceremony to Celebrate Commencement of Operations at its State-of-the-Art mRNA Vaccine Manufacturing Facility
SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today held a ceremony to celebrate the initiation of operations a...
2023-02-28 07:30
4546
Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index
HANGZHOU and SHAOXING, China, Feb. 27, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the Hang Seng Hong Kong-Listed Biotech Index (Index code: HSHKBIO), effective from March 13, 2023. HSHKBIO selects securities of multiple listed co...
2023-02-27 17:15
2506
Turacoz Paves the Way in Digital Content Management for Healthcare Communications with Veeva & Expert Training
UTRECHT, Netherlands and NEW DELHI, Feb. 27, 2023 /PRNewswire/ -- As digital
content gains importance in healthcare, the medical writing industry is
transitioning to digital content management.
2023-02-27 17:07
1588
Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive
MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the financial year ended31 December 2022. All figures are in AU$ unless otherwise stated. 2022 HIGHLIGHTS * Total Group revenue $160.1M ...
2023-02-27 14:37
1725
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
HAIKOU, China, Feb. 24, 2023 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effectiveMonday, March 6, 2023, with trading to begin on a split-adjusted basis ...
2023-02-25 05:05
4908
Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib
* With the efficacy comparable to rival drugs, Oscotec plans to advance to the next step, leaving the door open for partnership PANGYO, South Korea, Feb. 24, 2023 /PRNewswire/ -- Oscotec Inc. announced topline results for Phase 2 trial evaluating the efficacy, safety and tolerability of cevidop...
2023-02-24 22:00
3311
Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
* Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval inEurope * The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies PARIS, Feb. 24, 2023 /PRNewswire/ -- Servier, a global pharmaceutical company, today announ...
2023-02-24 21:29
2804
Porton Advanced and Yinjia Biosciences Partner to Enhance CDMO Technology Platform
SUZHOU, China, Feb. 24, 2023 /PRNewswire/ -- On February 20, 2023, Porton Advanced Solutions Ltd. (Porton Advanced) and Yinjia (Shanghai) Biosciences Co., Ltd. (Yinjia Biosciences) announced a strategic partnership in developing core protein raw materials for cell and gene therapy (CGT) and test ...
2023-02-24 20:00
1629
Dr. Lilly Xu Named President of Shanghai ChemPartner
SHANGHAI, Feb. 23, 2023 /PRNewswire/ -- ChemPartner
2023-02-24 05:53
1948
HAVAS HEALTH & YOU AND THE AMERICAN PARKINSON DISEASE ASSOCIATION LAUNCH SEXUAL WELLNESS CAMPAIGN PARKINSEX
Activation Advances Nonclinical Strategies for People with Parkinson's to Deepen Intimacy NEW YORK, Feb. 23, 2023 /PRNewswire/ -- Parkinson's disease affects more than ten million people worldwide and the prevalence of sexual dysfunction is disproportionately high in patients, causing partners t...
2023-02-23 22:15
2416
TB Alliance Announces David Norton as Board Chair
NEW YORK, Feb. 23, 2023 /PRNewswire/ -- The TB Alliance Board of Directors has electedDavid Norton as Chairperson of the Board. In this role, David will provide leadership to a diverse Board committed to advancing the vision of TB Alliance. "David Norton has contributed greatly to TB Alliance's ...
2023-02-23 22:00
2269
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China
SAN DIEGO, Feb. 23, 2023 /PRNewswire/ -- Today, Invivoscribe announced that its Shanghai lab in China has received CAP accreditation. The College of American Pathologists (CAP) is a professional organization that accredits clinical laboratories across the world. The CAP accreditation process is ...
2023-02-23 22:00
2437
Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymp...
2023-02-23 15:02
1600
Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901
CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class C...
2023-02-23 13:01
1647
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901
HONG KONG, Feb. 22, 2023 /PRNewswire/ -- Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudi...
2023-02-23 12:26
2213
Dawn Health partners with leading pharmaceutical company to transform chronic care
COPENHAGEN, Denmark, Feb. 23, 2023 /PRNewswire/ -- Dawn Health, a global leader in digital health, today announced a strategic partnership with Novartis, one of the leading medicines companies in the world, to support the development of a platform that enables the effective remote monitoring and ...
2023-02-23 12:16
1567
Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration
* Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea® Biosimilar (ALT-L9) clinical development and licensing-out discussions. * Early 2024 projected for Phase 3 completion and product launch in Europe expected after obtaining approval in the first half of 2025. DAEJEON, So...
2023-02-22 22:00
1891
150th Anniversary of Dr. Hansen's Discovery of M. leprae Is Opportunity to Examine Past, Present and Future of Leprosy
TOKYO, Feb. 22, 2023 /PRNewswire/ -- The University of Bergen, Norway and Sasakawa Leprosy (Hansen's Disease) Initiative will hold an event inBergen on Feb. 28, 2023, to mark the 150th anniversary of Dr. Gerhard Armauer Hansen's discovery of the leprosy bacillus,M. leprae, in 1873. On the same da...
2023-02-22 22:00
1913
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Multiple achievements made in China-Hungary BRI conference
[Picked up by 310 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 282 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 257 media titles]
2024-05-02 01:21
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
6663
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
5836
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
4657
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
4323
